A former AstraZeneca employee and member of a company due diligence team has agreed to settle insider trading charges brought by the Securities and Exchange Commission (SEC).  

Weiguo Zhai allegedly engaged in illegal insider trading prior to AstraZeneca’s announcement in 2023 that it would acquire Icosavax. Zhai was a member of the due diligence team that evaluated Icosavax prior to the acquisition.

Learn More
Already a member? Sign in to an existing account.

Adrianne Appel writes regulatory news, policy, and trends for Compliance Week. She previously reported about policy developments for Bloomberg Law and Bloomberg Government. Email: adrianne.appel@complianceweek.com LinkedIn:...